EX-FILING FEES 14 ex_778979.htm EXHIBIT FILING FEES ex_778979.htm

Exhibit 107

 

Calculation of Filing Fee Tables

F-1

(Form Type)

GenEmbryomics Limited

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

 

   

Security

Type

 

Security

Class

Title

 

Fee
Calculation
or Carry
Forward
Rule

 

Amount
Registered

   

Proposed
Maximum
Offering

Price Per
Share(1)

   

Proposed
Maximum
Aggregate

Offering
Price

   

Fee Rate

   

Amount of
Registration
Fee

 

Carry
Forward
Form

Type

 

Carry
Forward

File
Number

 

Carry
Forward
Initial
effective

date

 

Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward

Newly Registered Securities

Fees To be Paid

 

Equity

 

Ordinary shares, without par value

 

Rule 457(o)

    1,259,250       4.75     $ 5,981,437.50 (2)      0.00015310     $ 915.76                
   

Equity

 

Ordinary shares, without par value

 

Rule 457(g)

    75,555 (3)      5.225       986,937.19 (2)      0.00015310       151.11                
   

Equity

 

Ordinary shares, without par value

 

Rule 457(o)

    1,072,350 (4)      4.75       5,093,662.50       0.00015310       779.84                

 

                                                                 

 

   

Total Offering Amounts

            US$ 12,062,037.19             $ 1,846.71                
   

Total Fees Previously Paid

                              0.00                
   

Total Fee Offsets

                              0.00                
   

Net Fee Due

 1,846.71                

 

 

(1)

Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the securities being registered hereunder include such indeterminate number of additional ordinary shares as may be issued after the date hereof as a result of share sub-divisions, share capitalization or similar transactions.

 

(2)

Includes an additional 15% related to the exercise in full of the over-allotment option.

 

(3)

Represents 6% of the total number of ordinary shares sold in this offering and consists of 75,555 ordinary shares issuable upon the exercise of Representative’s Warrant for $5.225 per share.

 

(4)

Includes 1,072,350 ordinary shares that may be sold by certain selling shareholders under the Resale Prospectus.